These are this Friday’s top analyst upgrades, downgrades and initiations from Wall Street analysts.
Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) was downgraded to Neutral from Buy at Roth Capital.
Allergan Inc. (NYSE: AGN) was raised to Outperform from Market Perform at Leerink, on the heels of the stock falling – too much of a drop according to the firm.
Ann Inc. (NYSE: ANN) was downgraded to Neutral from Buy at UBS.
Barrick Gold Corp. (NYSE: ABX) was reiterated as Buy at Goldman Sachs, but the gold giant was added to the prized Conviction Buy List with a $22 price target (versus $18.49 close).
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was started as Overweight and with a $20 price target (versus $12.90 close) at J.P. Morgan.
Delek US Holdings, Inc. (NYSE: DK) was raised to Outperform from Market Perform at Cowen & Co.
Hibbett Sports, Inc. (NASDAQ: HIBB) was downgraded to Underperform from Neutral at Credit Suisse. Sterne Agee also downgraded Hibbett to Neutral.
ALSO READ: 4 DJIA Stocks To Buy That Are Down In 2014
Mylan, Inc. (NASDAQ: MYL) was downgraded to Sector Perform from Outperform and the price target was cut to $53 from $60 at RBC Capital Markets.
Nimble Storage, Inc. (NYSE: NMBL) was started as Outperform with a $33 price target at Wells Fargo.
NVIDIA Corp. (NASDAQ: NVDA) was raised to Buy from Hold with a $23 price target at Needham & Co.
POZEN Inc. (NASDAQ: POZN) was raised to Buy from Hold at Ascendiant Capital.
Rubicon Technology, Inc. (NASDAQ: RBCN) was downgraded to Hold from Buy and the price target was cut to $8 from $10 at Canaccord Genuity. Also, J.P. Morgan downgraded Rubicon to Neutral from Overweight, and it cut the price target to $8 from $13.
Zynga Inc. (NASDAQ: ZNGA) shares were down 8% at $2.68 in active trading on Friday morning after poor revenues and lower guidance. Multiple firms have lowered their target prices. Its price target was cut to $4 from $5 at Canaccord Genuity. Sterne Agee lowered its earnings estimates. Macquarie cut its price target to $3. Baird lowered its target to $3 from $4 in the call.
ALSO READ: 4 Biotech Stocks That Analysts Expect To Double (Or More!)
In case you missed Thursday’s top analyst upgrades and downgrades, they were in Aetna, AOL, Chesapeake, JD.Com, Skyworks, and about a dozen more.
Top Gaining Stocks
Top Losing Stocks